CXCL1和CXCL8:鉴别非小细胞肺癌肺内转移和多种原发肿瘤的可靠和可行的生物标志物。

IF 2.2 4区 医学 Q3 ONCOLOGY
Cancer Biomarkers Pub Date : 2025-04-01 Epub Date: 2025-04-15 DOI:10.1177/18758592241308730
Ao Liu, Tianlin Sun, Tong Qiu, Yunqing Chen, Huiyang Qi, Wenxing Du, Zhe Wu, Zhan Huang, Wenqing Su, Changbin Zhu, Wenjie Jiao
{"title":"CXCL1和CXCL8:鉴别非小细胞肺癌肺内转移和多种原发肿瘤的可靠和可行的生物标志物。","authors":"Ao Liu, Tianlin Sun, Tong Qiu, Yunqing Chen, Huiyang Qi, Wenxing Du, Zhe Wu, Zhan Huang, Wenqing Su, Changbin Zhu, Wenjie Jiao","doi":"10.1177/18758592241308730","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectiveIn NSCLC, the main approach to differentiate between intrapulmonary metastases (IPM) and multiple primary lung cancer (MPLC) is to integrate histopathological and genomic information. Here, we identified viable biomarkers that can distinguish IPM from MPLC by integrating comprehensive genomic profiling (CGP) and targeted RNA sequencing.MethodsWe retrospectively collected tissues from at least two lesions in 34 patients. 29 and 5 out of 34 patients determined as pathologic MPLC (pMPLC) and pathologic IPM, respectively, according to Martini-Melamed criteria (M-M criteria). A comprehensive investigation at genomic and transcriptomic level was conducted.ResultsNine of the 29 pMPLCs shared trunk mutations in their lesions and were consequently reclassified as IPM. Survival analyses revealed that classification integrated M-M criteria and mutational profiling could distinguish IPM/MPLC more accurately. Further exploration at the transcriptomic level revealed elevated expression levels of genes related to epithelial-mesenchymal transition and immunomodulatory pathways in IPM. Notably, the expression of <i>CXCL1</i> and <i>CXCL8</i> was significantly upregulated in IPM.ConclusionsWe found that the expression of <i>CXCL1</i> and <i>CXCL8</i> in any tumor lesion within a patient could reliably indicate IPM. Additionally, assessing the transcriptional levels of <i>CXCL1</i> and <i>CXCL8</i> also provide a dependable and practical approach to identify IPM from MPLC.</p>","PeriodicalId":56320,"journal":{"name":"Cancer Biomarkers","volume":"42 4","pages":"18758592241308730"},"PeriodicalIF":2.2000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CXCL1 and CXCL8: Reliable and feasible biomarkers differentiating intrapulmonary metastasis from multiple primary neoplasms in non-small cell lung cancers.\",\"authors\":\"Ao Liu, Tianlin Sun, Tong Qiu, Yunqing Chen, Huiyang Qi, Wenxing Du, Zhe Wu, Zhan Huang, Wenqing Su, Changbin Zhu, Wenjie Jiao\",\"doi\":\"10.1177/18758592241308730\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectiveIn NSCLC, the main approach to differentiate between intrapulmonary metastases (IPM) and multiple primary lung cancer (MPLC) is to integrate histopathological and genomic information. Here, we identified viable biomarkers that can distinguish IPM from MPLC by integrating comprehensive genomic profiling (CGP) and targeted RNA sequencing.MethodsWe retrospectively collected tissues from at least two lesions in 34 patients. 29 and 5 out of 34 patients determined as pathologic MPLC (pMPLC) and pathologic IPM, respectively, according to Martini-Melamed criteria (M-M criteria). A comprehensive investigation at genomic and transcriptomic level was conducted.ResultsNine of the 29 pMPLCs shared trunk mutations in their lesions and were consequently reclassified as IPM. Survival analyses revealed that classification integrated M-M criteria and mutational profiling could distinguish IPM/MPLC more accurately. Further exploration at the transcriptomic level revealed elevated expression levels of genes related to epithelial-mesenchymal transition and immunomodulatory pathways in IPM. Notably, the expression of <i>CXCL1</i> and <i>CXCL8</i> was significantly upregulated in IPM.ConclusionsWe found that the expression of <i>CXCL1</i> and <i>CXCL8</i> in any tumor lesion within a patient could reliably indicate IPM. Additionally, assessing the transcriptional levels of <i>CXCL1</i> and <i>CXCL8</i> also provide a dependable and practical approach to identify IPM from MPLC.</p>\",\"PeriodicalId\":56320,\"journal\":{\"name\":\"Cancer Biomarkers\",\"volume\":\"42 4\",\"pages\":\"18758592241308730\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Biomarkers\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/18758592241308730\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/18758592241308730","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的在非小细胞肺癌(NSCLC)中,鉴别肺内转移(IPM)和多原发肺癌(MPLC)的主要方法是整合组织病理和基因组信息。在这里,我们通过整合综合基因组分析(CGP)和靶向RNA测序,确定了可以区分IPM和MPLC的可行生物标志物。方法回顾性收集34例患者至少2处病变组织。根据Martini-Melamed标准(M-M标准),34例患者中分别有29例和5例诊断为病理性MPLC (pMPLC)和病理性IPM。在基因组和转录组水平上进行了全面的调查。结果29例pmplc中有9例在病变中有主干突变,因此被重新分类为IPM。生存分析显示,分类综合M-M标准和突变谱可以更准确地区分IPM/MPLC。转录组学水平的进一步研究表明,IPM中与上皮-间质转化和免疫调节途径相关的基因表达水平升高。值得注意的是,在IPM中,CXCL1和CXCL8的表达显著上调。结论我们发现CXCL1和CXCL8在患者任何肿瘤病变中的表达都可以可靠地指示IPM。此外,评估CXCL1和CXCL8的转录水平也为从MPLC中识别IPM提供了可靠和实用的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CXCL1 and CXCL8: Reliable and feasible biomarkers differentiating intrapulmonary metastasis from multiple primary neoplasms in non-small cell lung cancers.

ObjectiveIn NSCLC, the main approach to differentiate between intrapulmonary metastases (IPM) and multiple primary lung cancer (MPLC) is to integrate histopathological and genomic information. Here, we identified viable biomarkers that can distinguish IPM from MPLC by integrating comprehensive genomic profiling (CGP) and targeted RNA sequencing.MethodsWe retrospectively collected tissues from at least two lesions in 34 patients. 29 and 5 out of 34 patients determined as pathologic MPLC (pMPLC) and pathologic IPM, respectively, according to Martini-Melamed criteria (M-M criteria). A comprehensive investigation at genomic and transcriptomic level was conducted.ResultsNine of the 29 pMPLCs shared trunk mutations in their lesions and were consequently reclassified as IPM. Survival analyses revealed that classification integrated M-M criteria and mutational profiling could distinguish IPM/MPLC more accurately. Further exploration at the transcriptomic level revealed elevated expression levels of genes related to epithelial-mesenchymal transition and immunomodulatory pathways in IPM. Notably, the expression of CXCL1 and CXCL8 was significantly upregulated in IPM.ConclusionsWe found that the expression of CXCL1 and CXCL8 in any tumor lesion within a patient could reliably indicate IPM. Additionally, assessing the transcriptional levels of CXCL1 and CXCL8 also provide a dependable and practical approach to identify IPM from MPLC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cancer Biomarkers
Cancer Biomarkers ONCOLOGY-
CiteScore
5.20
自引率
3.20%
发文量
195
审稿时长
3 months
期刊介绍: Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信